Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing observational safety study of tazemetostat in relapsed or refractory follicular lymphoma with EZH2 mutation in Japan
2021-006398-41Phase 4
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tazemetostat in follicular lymphoma (FL), sponsored by Eisai Co., Ltd. Primary endpoint: Number of Subjects With Adverse Drug Reactions (ADRs).
02
Drugs
tazemetostat
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2021-006398-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006398-41.